MENU
+Compare
RPRX
Stock ticker: NASDAQ
AS OF
Jul 23, 12:36 PM (EDT)
Price
$35.92
Change
-$0.18 (-0.50%)
Capitalization
15.21B

RPRX Royalty Pharma plc Forecast, Technical & Fundamental Analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more

RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RPRX with price predictions
Jul 22, 2025

Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on July 22, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where RPRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 21, 2025. You may want to consider a long position or call options on RPRX as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RPRX moved out of overbought territory on June 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for RPRX turned negative on July 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RPRX broke above its upper Bollinger Band on June 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (18.178). P/E Ratio (14.735) is within average values for comparable stocks, (59.623). Projected Growth (PEG Ratio) (3.233) is also within normal values, averaging (2.529). Dividend Yield (0.024) settles around the average of (0.042) among similar stocks. P/S Ratio (9.398) is also within normal values, averaging (275.654).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RPRX is expected to report earnings to rise 152.55% to $1.04 per share on August 06

Royalty Pharma plc RPRX Stock Earnings Reports
Q2'25
Est.
$1.04
Q1'25
Missed
by $0.66
Q4'24
Missed
by $0.63
Q3'24
Missed
by $0.01
Q2'24
Est.
$0.97
The last earnings report on May 08 showed earnings per share of 41 cents, missing the estimate of $1.07. With 104.59K shares outstanding, the current market capitalization sits at 15.21B.
A.I.Advisor
published Dividends

RPRX paid dividends on June 10, 2025

Royalty Pharma plc RPRX Stock Dividends
А dividend of $0.22 per share was paid with a record date of June 10, 2025, and an ex-dividend date of May 16, 2025. Read more...
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
89
Web
https://www.royaltypharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QHY46.170.07
+0.16%
WisdomTree US Hi Yld Corp Bd
OILK41.28-0.07
-0.17%
ProShares K-1 Free Crude Oil ETF
CWEB43.55-0.21
-0.48%
Direxion Dly CSI CHN Itnet Bull 2X Shrs
EFZ13.94-0.07
-0.50%
ProShares Short MSCI EAFE
CONL63.00-1.57
-2.43%
GraniteShares 2x Long COIN Daily ETF

RPRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+0.17%
AXON - RPRX
48%
Loosely correlated
-0.60%
MDGL - RPRX
31%
Poorly correlated
-0.95%
ARRY - RPRX
30%
Poorly correlated
-3.94%
DTIL - RPRX
30%
Poorly correlated
+0.87%
QURE - RPRX
29%
Poorly correlated
-3.27%
More